atec™ INFORMED BY EOS

Q2 2026 FINANCIAL RESULTS

PAT MILES, CHAIRMAN & CEO | TODD KONING, EVP & CFO | AUGUST 4, 2026

FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue, balance sheet, growth, adjusted EBITDA, profitability, free cash flow, and financial outlook and commitments; planned product launches, timelines, introductions, regulatory submissions or clearances; and the Company's ability to compel surgeon adoption and drive procedural growth; and the expected reduction in interest expense and related cost savings over the life of the new credit facility, including assumptions regarding borrowing costs, interest rates, and the utilization of the facility. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding and the form of such funding; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations; changes in interest rates or credit market conditions that could affect the anticipated borrowing cost savings; and the Company's ability to satisfy the terms and covenants of the new credit facility. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the U.S. Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

INDUSTRY-LEADING PROFITABLE GROWTH

Q2 2026 HIGHLIGHTS

$214M
Total Revenue

17%
Surgical Revenue Growth

20%
Case Volume Growth

24%
Net New Surgeon Growth

$17M
EOS Revenue

$36M
Adjusted EBITDA

$1M
Free Cash Generated

 | Reference non-GAAP reconciliation in appendix

atec INFORMED BY EOS

Q2 REVENUE PERFORMANCE

STRONG REVENUE GROWTH DRIVEN BY SURGICAL VOLUME

	Q2 2026	YOY$	YOY%
Surgical Revenue	$196M	$28M	17%
EOS Revenue	$17M	-	0%
TOTAL REVENUE	**$214M**	**$28M**	**15%**

$28M

Surgical Revenue
YoY $ Growth

- 20% surgical volume growth driven by strong adoption of our procedural thesis
- Revenue per case down 2.7% year-over-year reflecting strong cervical & international performance and lower biologics attachment
- Revenue per case growth year-over-year across lateral, ALIF and cervical procedures

| May not foot due to rounding | Reference non-GAAP reconciliation in appendix

Q2 2026 NON-GAAP P&L HIGHLIGHTS

DISCIPLINED EXECUTION DRIVING PROFITABILITY—EBITDA GROWTH OUTPACING REVENUE GROWTH

	Q2 2026	YOY
TOTAL REVENUE	**$214M**	**15%**
Gross Margin %	72.5%	260 bps
R&D %	6.8%	(80 bps)
SG&A %	56.2%	(180 bps)
Total Operating Expense %	63.0%	(260 bps)
OP PROFIT MARGIN %	**9.4%**	**510 bps**
ADJUSTED EBITDA $	**$36M**	**53%**
% of Sales	16.8%	420 bps



- Gross margin improvements driven by inventory efficiency, cost improvements and product mix
- Overall operating expenses decreased 260 bps YoY
- Adj. EBITDA grew 420 bps YoY; drop through of 45% YoY

atec INFORMED BY EOS

| May not foot due to rounding | Reference non-GAAP reconciliation in appendix

Q2 BALANCE SHEET

GENERATING CASH FLOW WITH AN IMPROVED CAPITAL STRUCTURE

BALANCE SHEET	Q2 2026
Cash	$119M
Available Borrowing[1]	$85M
CASH + AVAILABLE CASH	**$204M**

TERM LOAN & REVOLVING CREDIT FACILITY

- ✓ Anchored by JP Morgan and TD Cowen
- ✓ Consolidates two legacy facilities into one
- ✓ Saves $6M+ in interest annually
- ✓ Extends maturity to 2031

LOAN	CAPACITY	MATURITY	RATE
TLA & RCF	$300M	May '31	SOFR + 275

CASH FLOW	Q2 2026
Operating Cash Flow[2]	$34M
Inventory and PP&E	($33M)
FREE CASH FLOW[3]	**$1M**

- ✓ Generated positive free cash flow
- ✓ 4th consecutive quarter of trailing twelve-month FCF
- ✓ Significant 1H investment to support 2H revenue ramp

| [1]The Company had $85M of undrawn credit available on its revolving line of credit at period end | [2]GAAP cash provided by operating activities less cash used on inventory |
[3]Free cash flow defined as cash generated by operating activities less PP&E

2026 REVENUE OUTLOOK

CONFIDENCE IN THE FULL YEAR WITH GROWTH DRIVEN BY STRONG SURGICAL DEMAND

$882M
Total Revenue

	FY'26E	YOY
Surgical Revenue	$805M	17%
EOS Revenue	$77M	0%
TOTAL REVENUE	**$882M**	**15%**

$118M
YoY Topline Growth

2026 FINANCIAL OUTLOOK

AFFIRMING REVENUE & RAISING PROFITABILITY

GROWTH LEADERSHIP

$882M

Total revenue;
15% growth

POWERFUL LEVERAGE

$140M

Adjusted EBITDA;
16% margin

FREE CASH FLOW

$20M

Investing in growth and
generating cash

INDUSTRY-LEADING PROFITABLE GROWTH & INNOVATION

OUR STRATEGY REMAINS STEADFAST

DELIVERING ON THE FUNDAMENTALS OF OUR LONG-TERM GROWTH ALGORITHM

1 CREATE CLINICAL DISTINCTION

Architect unparalleled procedural solutions that improve patient outcomes

2 COMPEL SURGEON ADOPTION

Earn loyalty through differentiated training, technology, and clinical value

3 EXPAND, ELEVATE & ENABLE SALES FORCE

Build a high-performing, aligned sales force designed to scale and win

PROCEDURAL CLINICAL DISTINCTION

COMPELLING SURGEON ADOPTION — 20% CASE VOLUME & 24% NET NEW SURGEON GROWTH YOY





DISTINCTION EARNS TRUST. TRUST EXPANDS UTILIZATION.





EOS IMAGING IS THE ENTRY POINT

ADVANCING FROM AN IMAGING PLATFORM TO AN INFORMATICS MOAT AT LEADING INSTITUTIONS



ACCESS

Entryway into leading, most prestigious institutions and KOL surgeons. Establishes ATEC rep presence in high-value strategic accounts

EOS DATA ADVANTAGE IS UNDENIABLE

CONVERTING ACCESS INTO HARDWARE PULL-THROUGH AND STRUCTURED LONGITUDINAL DATA

CLINIC INTEGRATION

Embedded beyond the O.R. into pre- and post-op clinical workflow, becoming standard practice for entire care team

EOS INSIGHT® PLAN

Data-driven, patient-specific plan aligns ATEC rep with procedural needs, enabling curated delivery of inventory

PATIENT-SPECIFIC RODS

Rods make ATEC rep integral to case execution, locking out competition and expanding hardware pull-through

COMPOUNDING DATA = LONG-TERM MOAT

Growing volume of structured imaging + longitudinal outcomes data enables continuous learning and informs future AI capabilities



32% AVERAGE REVENUE GROWTH ACROSS ESTABLISHED ATEC USERS AFTER EOS INSIGHT® ADOPTION



INDISPENSABLE IN THE O.R.

INTEGRATING ACTIONABLE INTELLIGENCE INTO EVERY STEP OF SURGICAL EXECUTION

SOLUTIONS FOR COMPLEX DEFORMITY

PROCEDURALIZED HARDWARE & INFORMATICS PURPOSE-BUILT FOR THE MOST COMPLEX OF CASES

DIAGNOSIS
& PLANNING

MOST-COVETED IMAGING

AUTOMATED ALIGNMENT

3D SURGICAL PLANNING WITH AXIAL ROTATION

SURGICAL
EXECUTION

PEDIATRIC POSITIONING

INTRAOP RECONCILIATION OF CORRECTION



BEST-IN-CLASS FIXATION



NEUROMONITORING

FOCAL REPLICATION OF CLINICAL MODEL

EXPORTING & SCALING CLINICAL DISTINCTION TO UNLOCK GROWTH IN MOST ATTRACTIVE MARKETS



GROWTH CATALYSTS

PROCEDURAL INNOVATION
DRIVE CONVOYED SALES THROUGH NEW PRODUCTS

LATERAL DISTINCTION
EXPAND NEW SURGEON FUNNEL AND UTILIZATION OF OUR ENTIRE PORTFOLIO

EOS & EOS INSIGHT®
SECURE NEW ACCESS, SCALE MATURE ACCOUNTS, EXPAND UTILIZATION

DEFORMITY & PEDIATRICS
GROW INFLUENCE AND LEADERSHIP ACROSS THE MOST COMPLEX CASES

VALENCE® PROCEDURAL INTEGRATION
BUILD UNIFIED ECOSYSTEM THAT ELEVATES SURGICAL EXECUTION

INTERNATIONAL REPLICATION
EXPORT CLINICAL MODEL TO UNLOCK GROWTH IN FOCAL, ATTRACTIVE MARKETS

MAGNET FOR TOP TALENT
COMPEL SURGEON ADOPTION THROUGH FOCUS ON CLINICAL DISTINCTION

αtec™

INFORMED BY EOS

THE PREFERRED DESTINATION IN SPINE.

APPENDIX

SUPPLEMENTAL FINANCIAL INFORMATION

HISTORICAL GAAP P&L TREND - CONSOLIDATED ($000's)

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Revenue from products and services	$ 138,477	$ 145,573	$ 150,719	$ 176,793	$ 611,562	$ 169,180	$ 185,544	$ 196,503	$ 212,928	$ 764,155	$ 192,108	$ 213,513
Cost of sales	41,126	42,979	47,990	55,205	187,300	53,184	56,443	59,203	63,437	232,267	55,632	59,415
Gross profit	**97,351**	**102,594**	**102,729**	**121,588**	**424,262**	**115,996**	**129,101**	**137,300**	**149,491**	**531,888**	**136,476**	**154,098**
Operating expenses:												
Research and development	18,012	19,105	20,357	23,244	80,718	16,582	18,276	18,679	22,281	76,268	17,560	18,174
Sales, general and administrative	113,727	112,731	109,200	114,541	450,199	127,017	118,507	124,303	128,699	498,526	137,057	134,001
Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525	(86)
Amortization of acquired intangibles	3,854	3,836	3,848	4,720	16,258	4,103	3,803	3,731	3,873	15,060	3,915	3,917
Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-	-
Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-	-
Total operating expenses	**140,692**	**137,901**	**136,432**	**145,406**	**560,431**	**160,287**	**142,186**	**153,233**	**158,310**	**614,016**	**159,057**	**156,006**
Operating Loss	**(43,341)**	**(35,307)**	**(33,703)**	**(23,818)**	**(136,169)**	**(44,291)**	**(13,085)**	**(15,933)**	**(8,819)**	**(82,128)**	**(22,581)**	**(1,908)**
Other expense, net:												
Cash interest expense, net	(4,283)	(4,754)	(5,417)	(5,967)	(20,421)	(5,356)	(5,289)	(5,312)	(5,184)	(21,141)	(4,953)	(4,374)
Noncash interest expense, net	(1,058)	(1,061)	(1,155)	(1,184)	(4,458)	(2,485)	(7,020)	(7,566)	(7,710)	(24,781)	(6,768)	(6,590)
Loss on debt extinguishment	-	-	-	-	-	(17,576)	-	-	-	(17,576)	-	(11,883)
(Loss) gain on derivative liability	-	-	-	-	-	17,400	(16,780)	-	-	620	-	-
Other (expense) income, net	118	156	623	(1,922)	(1,025)	337	993	307	(34)	1,603	446	(870)
Total other expense, net	**(5,223)**	**(5,659)**	**(5,949)**	**(9,073)**	**(25,904)**	**(7,680)**	**(28,096)**	**(12,571)**	**(12,928)**	**(61,275)**	**(11,275)**	**(23,717)**
Net loss before taxes	**(48,564)**	**(40,966)**	**(39,652)**	**(32,891)**	**(162,073)**	**(51,971)**	**(41,181)**	**(28,504)**	**(21,747)**	**(143,403)**	**(33,856)**	**(25,625)**
Income tax provision (benefit)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)	50	156
Net loss, GAAP	**$ (48,495)**	**$ (40,680)**	**$ (39,616)**	**$ (33,332)**	**$ (162,123)**	**$ (51,907)**	**$ (41,144)**	**$ (28,578)**	**$ (21,729)**	**$ (143,358)**	**$ (33,906)**	**$ (25,781)**
Net loss per share, GAAP	**$ (0.34)**	**$ (0.29)**	**$ (0.28)**	**$ (0.23)**	**$ (1.13)**	**$ (0.35)**	**$ (0.27)**	**$ (0.19)**	**$ (0.14)**	**$ (0.96)**	**$ (0.22)**	**$ (0.16)**
Weighted average shares outstanding, basic and diluted	**140,980**	**142,687**	**143,492**	**144,583**	**142,946**	**146,732**	**149,907**	**151,401**	**152,106**	**150,064**	**154,051**	**156,575**

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP RECONCILIATION - CONSOLIDATED ($000's)

NON-GAAP GROSS PROFIT & GROSS MARGIN	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Gross Profit, GAAP	$ 97,351	$ 102,594	$ 102,729	$ 121,588	$ 424,262	$ 115,996	$ 129,101	$ 137,300	$ 149,491	$ 531,888	$ 136,476	$ 154,098
+ Amortization of acquired intangible assets	307	307	308	(814)	108	50	64	65	66	245	66	65
+ Stock-based compensation	483	554	1,439	2,485	4,961	3,043	553	414	519	4,529	970	559
+ Purchase accounting adjustments on acquisitions	-	197	-	-	197	-	-	-	-	-	-	-
Non-GAAP Gross Profit	$ 98,141	$ 103,652	$ 104,476	$ 123,259	$ 429,528	$ 119,089	$ 129,718	$ 137,779	$ 150,076	$ 536,662	$ 137,512	$ 154,722
Gross Margin, GAAP	70.3%	70.5%	68.2%	68.8%	69.4%	68.6%	69.6%	69.9%	70.2%	69.6%	71.0%	72.2%
+ Amortization of acquired intangible assets	0.2%	0.2%	0.2%	-0.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
+ Stock-based compensation	0.3%	0.4%	1.0%	1.4%	0.8%	1.8%	0.3%	0.2%	0.2%	0.6%	0.5%	0.3%
+ Purchase accounting adjustments on acquisitions	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Non-GAAP Gross Margin	70.9%	71.2%	69.3%	69.7%	70.2%	70.4%	69.9%	70.1%	70.5%	70.2%	71.6%	72.5%

NON-GAAP OPERATING EXPENSES	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Research & Development, GAAP	$ 18,012	$ 19,105	$ 20,357	$ 23,244	$ 80,718	$ 16,582	$ 18,276	$ 18,679	$ 22,281	$ 76,268	$ 17,560	$ 18,174
- Stock-based compensation in R&D	4,315	5,614	7,207	9,894	27,030	3,644	4,159	3,307	8,421	19,531	4,001	3,605
Non-GAAP R&D	13,697	13,491	13,150	13,350	53,688	12,938	14,117	15,372	13,860	56,737	13,559	14,569
Sales General & Administrative, GAAP	113,727	112,731	109,200	114,541	450,199	127,017	118,507	124,303	128,699	498,526	137,057	134,001
- Stock-based compensation in SG&A	12,524	10,792	8,816	9,154	41,286	15,631	10,912	12,658	10,458	49,659	18,688	13,983
- Other non-recurring expenses	-	1,608	-	-	1,608	-	-	-	-	-	-	-
Non-GAAP SG&A	101,203	100,331	100,384	105,387	407,305	111,386	107,595	111,645	118,241	448,867	118,369	120,018
Other Operating Expense, GAAP	8,953	6,065	6,875	7,621	29,514	16,688	5,403	10,251	7,330	39,222	4,440	3,831
- Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525	(86)
- Amortization of acquired intangibles assets	3,854	3,836	3,848	4,720	16,258	4,103	3,803	3,731	3,873	15,060	3,915	3,917
- Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-	-
- Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-	-
Non-GAAP Other Operating Expense	-	-	-	-	-	-	-	-	-	-	-	-
Total Non-GAAP Operating Expenses	$ 114,900	$ 113,822	$ 113,534	$ 118,737	$ 460,993	$ 124,324	$ 121,712	$ 127,017	$ 132,101	$ 505,604	$ 131,928	$ 134,587
Non-GAAP Operating Expenses as a % of Revenue												
Research & development	9.9%	9.3%	8.7%	7.6%	8.8%	7.6%	7.6%	7.8%	6.5%	7.4%	7.1%	6.8%
Sales, general & administrative	73.1%	68.9%	66.6%	59.6%	66.6%	65.8%	58.0%	56.8%	55.5%	58.7%	61.6%	56.2%
Total Non-GAAP Operating Expenses as a % of Revenue	83.0%	78.2%	75.3%	67.2%	75.4%	73.5%	65.6%	64.6%	62.0%	66.2%	68.7%	63.0%

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP RECONCILIATION - CONSOLIDATED ($000's)

ADJUSTED EBITDA	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Net loss, GAAP	$ (48,495)	$ (40,680)	$ (39,616)	$ (33,332)	$ (162,123)	$ (51,907)	$ (41,144)	$ (28,578)	$ (21,729)	$ (143,358)	$ (33,906)	$ (25,781)
Cash interest expense, net	4,283	4,754	5,417	5,967	20,421	5,356	5,289	5,312	5,184	21,141	4,953	4,374
Noncash interest expense, net	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781	6,768	6,590
Loss on debt extinguishment	-	-	-	-	-	17,576	-	-	-	17,576	-	11,883
(Loss) gain on derivative liability	-	-	-	-	-	(17,400)	16,780	-	-	(620)	-	-
Other (expense) income, net	(118)	(156)	(623)	1,922	1,025	(337)	(993)	(307)	34	(1,603)	(446)	870
Income tax provision (benefit)	(69)	(286)	(36)	441	50	(64)	(37)	74	(18)	(45)	50	156
Depreciation expense	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350	14,629	15,160
Amortization expense	4,161	4,143	4,156	3,906	16,366	4,153	4,316	4,267	4,406	17,142	4,506	4,637
Total EBITDA	**(25,456)**	**(15,429)**	**(13,056)**	**(3,810)**	**(57,751)**	**(24,384)**	**6,243**	**3,223**	**10,282**	**(4,636)**	**(3,446)**	**17,889**
+ Stock-based compensation	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719	23,659	18,147
+ Purchase accounting adjustments on acquisitions	-	197	-	-	197	-	-	-	-	-	-	-
+ Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525	(86)
+ Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-	-
+ Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-	-
+ Other non-recurring expenses	-	1,608	-	-	1,608	-	-	-	-	-	-	-
Total Adjusted EBITDA	**$ (3,035)**	**$ 5,565**	**$ 7,433**	**$ 20,624**	**$ 30,587**	**$ 10,519**	**$ 23,467**	**$ 26,122**	**$ 33,137**	**$ 93,245**	**$ 20,738**	**$ 35,950**
Adjusted EBITDA as a % of Revenue	***-2.2%***	***3.8%***	***4.9%***	***11.7%***	***5.0%***	***6.2%***	***12.6%***	***13.3%***	***15.6%***	***12.2%***	***10.8%***	***16.8%***

NON-GAAP EARNINGS (LOSS) PER SHARE	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Net Loss, GAAP	$ (48,495)	$ (40,680)	$ (39,616)	$ (33,332)	$ (162,123)	$ (51,907)	$ (41,144)	$ (28,578)	$ (21,729)	$ (143,358)	$ (33,906)	$ (25,781)
+ Stock-based compensation	17,322	16,960	17,462	21,533	73,277	22,318	15,624	16,379	19,398	73,719	23,659	18,147
+ Amortization of acquired intangible assets	4,161	4,143	4,156	3,906	16,366	4,153	3,867	3,796	3,939	15,305	3,981	3,982
+ Restructuring expenses	788	139	934	1,386	3,247	371	7	-	-	378	-	-
+ Transaction-related expenses	(117)	-	-	327	210	-	-	-	-	-	-	-
+ Litigation-related expenses	4,428	2,090	2,093	1,188	9,799	12,214	1,593	6,520	3,457	23,784	525	(86)
+ Loss on Debt extinguishment	-	-	-	-	-	17,576	-	-	-	17,576	-	11,883
+ (Loss) gain on derivative liability	-	-	-	-	-	(17,400)	16,780	-	-	(620)	-	-
+ Noncash interest expense, net	1,058	1,061	1,155	1,184	4,458	2,485	7,020	7,566	7,710	24,781	6,768	6,590
+ Foreign exchange impact	(119)	(44)	(624)	1,592	805	(312)	(308)	(29)	(60)	(708)	(429)	873
+ Long-term income tax rate adjustment	5,448	4,606	3,800	21	13,875	2,811	(848)	(1,563)	(3,283)	(2,766)	(218)	(4,255)
Non-GAAP net income (loss)	**$ (15,526)**	**$ (11,725)**	**$ (10,640)**	**$ (2,195)**	**$ (40,086)**	**$ (7,691)**	**$ 2,591**	**$ 4,091**	**$ 9,432**	**$ 8,091**	**$ 380**	**$ 11,353**
Non-GAAP net income (loss) per share	$ (0.11)	$ (0.08)	$ (0.07)	$ (0.02)	$ (0.28)	$ (0.05)	$ 0.02	$ 0.03	$ 0.06	$ 0.05	$ 0.00	$ 0.07
Weighted avg shares outstanding, basic and diluted	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064	154,051	156,575

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP P&L TREND - CONSOLIDATED ($000's)

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Revenue from products and services	$ 138,477	$ 145,573	$ 150,719	$ 176,793	$ 611,562	$ 169,180	$ 185,544	$ 196,503	$ 212,928	$ 764,155	$ 192,108	$ 213,513
Non-GAAP cost of sales	40,336	41,921	46,243	53,534	182,034	50,091	55,826	58,724	62,852	227,493	54,596	58,791
Non-GAAP gross profit	$ 98,141	$ 103,652	$ 104,476	$ 123,259	$ 429,528	$ 119,089	$ 129,718	$ 137,779	$ 150,076	$ 536,662	$ 137,512	$ 154,722
Non-GAAP Gross Margin	*70.9%*	*71.2%*	*69.3%*	*69.7%*	*70.2%*	*70.4%*	*69.9%*	*70.1%*	*70.5%*	*70.2%*	*71.6%*	*72.5%*
Non-GAAP Operating expenses:												
Non-GAAP research & development	13,697	13,491	13,150	13,350	53,688	12,938	14,117	15,372	13,860	56,737	13,559	14,569
Non-GAAP sales, general & administrative	101,203	100,331	100,384	105,387	407,305	111,386	107,595	111,645	118,241	448,867	118,369	120,018
Total non-GAAP operating expenses	$ 114,900	$ 113,822	$ 113,534	$ 118,737	$ 460,993	$ 124,324	$ 121,712	$ 127,017	$ 132,101	$ 505,604	$ 131,928	$ 134,587
Non-GAAP R&D as % of revenue	*9.9%*	*9.3%*	*8.7%*	*7.6%*	*8.8%*	*7.6%*	*7.6%*	*7.8%*	*6.5%*	*7.4%*	*7.1%*	*6.8%*
Non-GAAP SG&A as % of revenue	*73.1%*	*68.9%*	*66.6%*	*59.6%*	*66.6%*	*65.8%*	*58.0%*	*56.8%*	*55.5%*	*58.7%*	*61.6%*	*56.2%*
Total Non-GAAP OPEX as % of revenue	*83.0%*	*78.2%*	*75.3%*	*67.2%*	*75.4%*	*73.5%*	*65.6%*	*64.6%*	*62.0%*	*66.2%*	*68.7%*	*63.0%*
Non-GAAP operating income (loss)	(16,759)	(10,170)	(9,058)	4,522	(31,465)	(5,235)	8,006	10,762	17,975	31,058	5,584	20,135
Op income (loss) as % of revenue	*-12.1%*	*-7.0%*	*-6.0%*	*2.6%*	*-5.1%*	*-3.1%*	*4.3%*	*5.5%*	*8.4%*	*4.1%*	*2.9%*	*9.4%*
Cash interest expense	4,283	4,754	5,417	5,967	20,421	5,356	5,289	5,312	5,184	21,141	4,953	4,374
Other (expense) income	1	1,693	1	330	2,025	(25)	(685)	(278)	94	(895)	(17)	(3)
Long-term income tax rate adjustment	(5,517)	(4,892)	(3,836)	420	(13,825)	(2,875)	811	1,637	3,265	2,721	268	4,411
Non-GAAP net income (loss)	(15,526)	(11,725)	(10,640)	(2,195)	(40,086)	(7,691)	2,591	4,091	9,432	8,091	380	11,353
Non-GAAP net income (loss) per share	$ (0.11)	$ (0.08)	$ (0.07)	$ (0.02)	$ (0.28)	$ (0.05)	$ 0.02	$ 0.03	$ 0.06	$ 0.05	$ 0.00	$ 0.07
Weighted avg shares outstanding, basic and diluted	140,980	142,687	143,492	144,583	142,946	146,732	149,907	151,401	152,106	150,064	154,051	156,575
Non-GAAP operating income (loss)	(16,759)	(10,170)	(9,058)	4,522	(31,465)	(5,235)	8,006	10,762	17,975	31,058	5,584	20,135
Less: Other amortization expense	-	-	-	-	-	-	449	471	467	1,837.00	525	655
Less: Depreciation expense	13,724	15,735	16,491	16,102	62,052	15,754	15,012	14,889	14,695	60,350	14,629	15,160
Adjusted EBITDA	$ (3,035)	$ 5,565	$ 7,433	$ 20,624	$ 30,587	$ 10,519	$ 23,467	$ 26,122	$ 33,137	$ 93,245	$ 20,738	$ 35,950
Adj EBITDA as % of revenue	***-2.2%***	***3.8%***	***4.9%***	***11.7%***	***5.0%***	***6.2%***	***12.6%***	***13.3%***	***15.6%***	***12.2%***	***10.8%***	***16.8%***
Adj EBITDA drop through %	***14.5%***	***30.4%***	***24.2%***	***48.8%***	***30.7%***	***44.1%***	***44.8%***	***40.8%***	***34.6%***	***41.1%***	***44.6%***	***44.6%***

SUPPLEMENTAL FINANCIAL INFORMATION

REVENUE SUPPLEMENT

INFORMED BY EOS

	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Revenues:												
Products and services - Surgical	122,617	130,028	135,343	156,468	544,456	152,084	168,217	176,676	189,769	686,746	178,124	196,077
Products and services - EOS	15,860	15,545	15,376	20,325	67,106	17,096	17,327	19,827	23,159	77,409	13,984	17,436
Total revenue from products and services	**$ 138,477**	**$ 145,573**	**$ 150,719**	**$ 176,793**	**$ 611,562**	**$ 169,180**	**$ 185,544**	**$ 196,503**	**$ 212,928**	**$ 764,155**	**$ 192,108**	**$ 213,513**
Constant currency adjustments:												
Products and services - Surgical	67	18	(13)	(72)	-	180	80	75	93	428	(387)	(398)
Products and services - EOS	(88)	42	27	(146)	(165)	405	(167)	(435)	(589)	(786)	(727)	(352)
Revenue from products and services	(21)	60	14	(218)	(165)	585	(87)	(360)	(496)	(358)	(1,114)	(750)
TOTAL ADJUSTMENTS	**(21)**	**60**	**14**	**(218)**	**(165)**	**585**	**(87)**	**(360)**	**(496)**	**(358)**	**(1,114)**	**(750)**
Revenues at constant currency:												
Products and services - Surgical	122,684	130,046	135,330	156,396	544,456	152,264	168,297	176,751	189,862	687,174	177,737	195,679
Products and services - EOS	15,772	15,586	15,403	20,179	66,940	17,501	17,160	19,392	22,570	76,623	13,257	17,084
Total Revenue at Constant Currency	**$ 138,456**	**$ 145,632**	**$ 150,733**	**$ 176,575**	**$ 611,396**	**$ 169,765**	**$ 185,457**	**$ 196,143**	**$ 212,432**	**$ 763,797**	**$ 190,994**	**$ 212,763**

YOY GROWTH %	Q124	Q224	Q324	Q424	2024	Q125	Q225	Q325	Q425	2025	Q126	Q226
Products and services - Surgical	30%	27%	30%	28%	29%	24%	29%	31%	21%	26%	17%	17%
Products and services - EOS	5%	6%	6%	32%	13%	8%	11%	29%	14%	15%	-18%	1%
Total revenue from products and services	**27%**	**25%**	**27%**	**28%**	**27%**	**22%**	**27%**	**30%**	**20%**	**25%**	**14%**	**15%**
YOY growth % at constant currency:												
Products and services - Surgical	30%	27%	30%	28%	29%	24%	29%	31%	21%	26%	17%	16%
Products and services - EOS	2%	7%	9%	34%	13%	11%	10%	26%	12%	14%	-24%	0%
Total Revenue Growth % at Constant Currency	**26%**	**25%**	**28%**	**28%**	**27%**	**23%**	**27%**	**30%**	**20%**	**25%**	**13%**	**15%**